Literature DB >> 12807853

Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis.

L Nalysnyk1, K Fahrbach, M W Reynolds, S Z Zhao, S Ross.   

Abstract

OBJECTIVES: To quantify the incidence of major adverse events (AEs) occurring in hospital or within 30 days after surgery in patients undergoing coronary artery bypass graft (CABG) surgery and to identify risk factors for these AEs.
METHODS: Systematic review and analysis of studies published in English since 1990. Studies of isolated standard CABG reporting postoperative incidence of myocardial infarction (MI), stroke, gastrointestinal bleeding, renal failure, or death in hospital or within 30 days were eligible for inclusion. Incidence of these events was calculated overall and for selected patient groups defined by all elective CABG versus mixed (some non-elective); mean ejection fraction < or = 50% versus > 50%; mean age < or= 60 versus > 60 years; primary CABG versus some reoperations; randomised controlled trials versus cohort studies; and single centre versus multicentre studies. Odds ratios of selected AEs were computed according to group risk factors.
RESULTS: 176 studies (205 717 patients) met all inclusion criteria. The average incidence of major AEs occurring in-hospital was death (1.7%); non-fatal MI (2.4%); non-fatal stroke (1.3%); gastrointestinal bleeding (1.5%); and renal failure (0.8%). Thirty day mortality was 2.1%. Meta-analyses show that age > 70, female sex, low ejection fraction, history of stroke, MI, or heart surgery, and presence of diabetes or hypertension are all associated with increased 30 day mortality after CABG.
CONCLUSION: The incidence of major AEs in patients after CABG varies widely across studies and patient populations, and this heterogeneity must be controlled when using the literature to benchmark safety.

Entities:  

Mesh:

Year:  2003        PMID: 12807853      PMCID: PMC1767742          DOI: 10.1136/heart.89.7.767

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  A comparison of observational studies and randomized, controlled trials.

Authors:  K Benson; A J Hartz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 3.  Severe morbidity after coronary artery surgery.

Authors:  J Pepper
Journal:  Curr Opin Cardiol       Date:  2000-11       Impact factor: 2.161

Review 4.  Assessment of therapeutic safety in systematic reviews: literature review.

Authors:  E Ernst; M H Pittler
Journal:  BMJ       Date:  2001-09-08

5.  Systematic reviews: synthesis of best evidence for clinical decisions.

Authors:  D J Cook; C D Mulrow; R B Haynes
Journal:  Ann Intern Med       Date:  1997-03-01       Impact factor: 25.391

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group.

Authors:  D T Mangano; D Siliciano; M Hollenberg; J M Leung; W S Browner; P Goehner; S Merrick; E Verrier
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

  7 in total
  47 in total

1.  Prediction and prevention of upper gastrointestinal bleeding after cardiac surgery: a case control study.

Authors:  Mamatha Bhat; Martin Larocque; Marcos Amorim; Karl Herba; Myriam Martel; Benoît De Varennes; Alan Barkun
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

2.  An alternative approach to prescribing sternal precautions after median sternotomy, "Keep Your Move in the Tube".

Authors:  Jenny Adams; Ana Lotshaw; Emelia Exum; Mark Campbell; Cathy B Spranger; Jim Beveridge; Shawn Baker; Stephanie McCray; Tim Bilbrey; Tiffany Shock; Anne Lawrence; Baron L Hamman; Jeffrey M Schussler
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-01

3.  Coronary angiography in patients undergoing carotid artery stenting shows a high incidence of significant coronary artery disease.

Authors:  R Hofmann; A Kypta; C Steinwender; K Kerschner; M Grund; F Leisch
Journal:  Heart       Date:  2005-03-10       Impact factor: 5.994

Review 4.  Antifibrinolytic therapy: evidence, bias, confounding (and politics!).

Authors:  Paul Myles
Journal:  J Extra Corpor Technol       Date:  2007-12

5.  EUROSCORE: still gold standard or less?

Authors:  Christoph Bode; Malte Kelm
Journal:  Clin Res Cardiol       Date:  2009-05-05       Impact factor: 5.460

Review 6.  The comparative efficacy of percutaneous and surgical coronary revascularization in 2009: a review.

Authors:  Stephen A May; James M Wilson
Journal:  Tex Heart Inst J       Date:  2009

7.  Altering driving restrictions after median sternotomy.

Authors:  Richard Gach; Susan Triano; Doa El-Ansary; Robert Parker; Jenny Adams
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-26

8.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

9.  Polymorphisms in glutathione S-transferase are risk factors for perioperative acute myocardial infarction after cardiac surgery: a preliminary study.

Authors:  Viktória Kovacs; Balazs Gasz; Borbala Balatonyi; Luca Jaromi; Peter Kisfali; Balazs Borsiczky; Gabor Jancso; Nandor Marczin; Sandor Szabados; Bela Melegh; Alotti Nasri; Elisabeth Roth
Journal:  Mol Cell Biochem       Date:  2014-01-17       Impact factor: 3.396

Review 10.  Upper endoscopy in patients with acute myocardial infarction and upper gastrointestinal bleeding: results of a decision analysis.

Authors:  Patrick Yachimski; Chin Hur
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.